MA42367A - Formulation pharmaceutique pour le traitement de modifications inflammatoires du rectum - Google Patents

Formulation pharmaceutique pour le traitement de modifications inflammatoires du rectum

Info

Publication number
MA42367A
MA42367A MA042367A MA42367A MA42367A MA 42367 A MA42367 A MA 42367A MA 042367 A MA042367 A MA 042367A MA 42367 A MA42367 A MA 42367A MA 42367 A MA42367 A MA 42367A
Authority
MA
Morocco
Prior art keywords
rectum
treatment
pharmaceutical formulation
inflammatory changes
inflammatory
Prior art date
Application number
MA042367A
Other languages
English (en)
Other versions
MA42367B1 (fr
Inventor
Roland Greinwald
Ralf Mohrbacher
Markus Pröls
Rudolph Wilhelm
Original Assignee
Dr Falk Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Falk Pharma Gmbh filed Critical Dr Falk Pharma Gmbh
Publication of MA42367A publication Critical patent/MA42367A/fr
Publication of MA42367B1 publication Critical patent/MA42367B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA42367A 2015-07-08 2016-06-28 Formulation pharmaceutique pour le traitement de modifications inflammatoires de rectum MA42367B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15175806.7A EP3115037B1 (fr) 2015-07-08 2015-07-08 Formulation pharmaceutique pour le traitement de modifications inflammatoires de rectum
PCT/EP2016/064907 WO2017005524A1 (fr) 2015-07-08 2016-06-28 Formulation pharmaceutique pour le traitement de modifications inflammatoires du rectum

Publications (2)

Publication Number Publication Date
MA42367A true MA42367A (fr) 2018-05-16
MA42367B1 MA42367B1 (fr) 2023-02-28

Family

ID=53540667

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42367A MA42367B1 (fr) 2015-07-08 2016-06-28 Formulation pharmaceutique pour le traitement de modifications inflammatoires de rectum

Country Status (23)

Country Link
US (4) US10905699B2 (fr)
EP (2) EP3115037B1 (fr)
JP (1) JP6857644B2 (fr)
CN (1) CN107847435B (fr)
AU (1) AU2016290343B2 (fr)
CA (1) CA2986081C (fr)
DK (1) DK3319586T3 (fr)
EA (1) EA033153B1 (fr)
ES (2) ES2688119T3 (fr)
FI (1) FI3319586T3 (fr)
HR (1) HRP20230174T1 (fr)
HU (1) HUE061585T2 (fr)
IL (1) IL255247B (fr)
LT (1) LT3319586T (fr)
MA (1) MA42367B1 (fr)
MD (1) MD3319586T2 (fr)
PL (1) PL3319586T3 (fr)
PT (2) PT3115037T (fr)
RS (1) RS64020B1 (fr)
SI (1) SI3319586T1 (fr)
UA (1) UA120075C2 (fr)
WO (1) WO2017005524A1 (fr)
ZA (1) ZA201707777B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115529815B (zh) * 2021-04-27 2024-04-30 广州共禾医药科技有限公司 经直肠施用的奥司他韦或其药学上可接受的盐的药物组合物、及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB701831A (en) * 1950-10-19 1954-01-06 Rudolf Von Wuelfing Process for the production of suppositories containing medicaments
US3208907A (en) * 1961-11-13 1965-09-28 Lab Toraude Stabilized salicylate compositions
DE3709861A1 (de) * 1987-03-25 1988-10-06 Henkel Kgaa Emulgierende suppositoriengrundmassen und daraus hergestellte zaepfchen
JP2927830B2 (ja) * 1989-09-01 1999-07-28 東京田辺製薬株式会社 ダナゾール坐剤
IT1243379B (it) 1990-07-27 1994-06-10 Giuliani Spa Composizione farmaceutica adatta alla somministrazione rettale di principi attivi che esplicano un'azione di medicazione a livello del colon prevalentemente di tipo topico
DE29717252U1 (de) 1997-09-26 1998-02-19 Dr. Falk Pharma GmbH, 79108 Freiburg Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
DE19849737A1 (de) * 1998-10-28 2000-05-04 Falk Pharma Gmbh Kombinationsmittel zur Behandlung entzündlicher Darmerkrankungen
US20020085978A1 (en) * 2000-11-10 2002-07-04 Mina Buenafe Degradation-resistant glucocorticosteroid formulations
CU23203A1 (es) * 2002-12-27 2007-05-18 Ct Ingenieria Genetica Biotech Formulaciones que contienen agentes de accion trombolitica para su administracion por via rectal
JP5223307B2 (ja) * 2006-11-17 2013-06-26 大正製薬株式会社 坐剤
KR20100038098A (ko) * 2007-06-13 2010-04-12 제이 프라우다 산화 스트레스와 관련된 질병의 진단 및 치료용 물질 및 방법
JP2012509892A (ja) * 2008-11-26 2012-04-26 サティオゲン ファーマシューティカルズ，インク． サティオゲン類を含有する組成物及び使用の方法
WO2012022796A2 (fr) * 2010-08-20 2012-02-23 Boehringer Ingelheim International Gmbh Nouvelles combinaisons
CN102525883B (zh) * 2010-12-09 2013-05-08 丽珠集团丽珠制药厂 一种伏立康唑栓剂及其制备方法和用途
WO2015073846A1 (fr) 2013-11-15 2015-05-21 Salix Pharmaceuticals, Inc. Procédés de traitement de la rectocolite hémorragique

Also Published As

Publication number Publication date
EP3115037B1 (fr) 2018-08-15
NZ736749A (en) 2023-12-22
US20230364113A1 (en) 2023-11-16
CA2986081C (fr) 2024-02-20
CN107847435B (zh) 2021-07-27
EP3319586B1 (fr) 2023-01-18
IL255247B (en) 2020-11-30
US10905699B2 (en) 2021-02-02
RS64020B1 (sr) 2023-03-31
EP3115037A1 (fr) 2017-01-11
MD3319586T2 (ro) 2023-04-30
DK3319586T3 (da) 2023-02-27
IL255247A0 (en) 2017-12-31
LT3319586T (lt) 2023-03-10
MA42367B1 (fr) 2023-02-28
SI3319586T1 (sl) 2023-03-31
HUE061585T2 (hu) 2023-07-28
PT3115037T (pt) 2018-10-22
UA120075C2 (uk) 2019-09-25
US12472191B2 (en) 2025-11-18
ES2688119T3 (es) 2018-10-31
CN107847435A (zh) 2018-03-27
FI3319586T3 (fi) 2023-03-22
HRP20230174T1 (hr) 2023-04-14
EP3319586A1 (fr) 2018-05-16
JP2018519345A (ja) 2018-07-19
EA033153B1 (ru) 2019-09-30
US20210100819A1 (en) 2021-04-08
US20180200268A1 (en) 2018-07-19
PT3319586T (pt) 2023-02-14
JP6857644B2 (ja) 2021-04-14
ES2938358T3 (es) 2023-04-10
WO2017005524A1 (fr) 2017-01-12
CA2986081A1 (fr) 2017-01-12
US20260053818A1 (en) 2026-02-26
AU2016290343A1 (en) 2017-11-16
US11738032B2 (en) 2023-08-29
AU2016290343B2 (en) 2020-10-15
PL3319586T3 (pl) 2023-05-08
ZA201707777B (en) 2018-11-28
EA201792685A1 (ru) 2018-07-31

Similar Documents

Publication Publication Date Title
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
EP3436002A4 (fr) Combinaisons pharmaceutiques pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
MA45146A (fr) Dérivés de pyrazolopyridine pour le traitement du cancer
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
EP3494142A4 (fr) Anticorps anti-siglec-7 pour le traitement du cancer
EP3432927A4 (fr) Inhibiteurs trispécifiques pour le traitement du cancer
FR3046933B1 (fr) Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3474854A4 (fr) Associations médicamenteuses pour le traitement du cancer
EP3374502A4 (fr) Procédés pour le traitement de dystrophies cornéennes
EP3285773A4 (fr) Polythérapie pour le traitement du cancer
EP3347469A4 (fr) Méthodes et compositions pour le traitement du glaucome
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
EP3359192A4 (fr) Polythérapie pour le traitement du cancer
MA42999A (fr) Polythérapie pour le traitement de malignités
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3331510A4 (fr) Thérapies combinatoires pour le traitement du cancer
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3344325A4 (fr) Administration locale de médicaments pour le traitement de l'asthme
EP3363450A4 (fr) Composition de médecine traditionnelle chinoise pour le traitement du psoriasis